Adastra Holdings Ltd · CSE:XTRX
Adastra — Investor Presentation (September 2023)
17 slides from Adastra's investor presentation, September 2023
Slide 1: Investor Presentation
INVESTOR PRESENTATION CANNABIS THROUGH ART AND SCIENCE September 2023
Slide 2: Who Are We?
WHO ARE WE? Adastra is a leading cannabis processor, producer, and co-manufacturer catering to both the adult-use and medical cannabis sectors. We distribute premium cannabis products, along with managing a portfolio of successful proprietary brands: Phyto Extractions and Endgame boast a robust pres
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS Strategic Pursuit of Licenses and Amendments • Standard Processing Licence, Flower Sales Licence, Analytical Testing Licence, Medical Sales Licence • Controlled Substances Dealer's Licence including synthesis, propagation, cultivation, and harvesting of psychedelic mushrooms fo
Slide 4: Expanding Capabilities to Meet Market Demand
EXPANDING CAPABILITIES TO MEET MARKET DEMAND SUMMER 2022 WINTER 2022 Summer 2023 • Additional Endgame SKUs brought to market ex: • Infused pre rolls and flower SKUs launched into market • In August, Health Canada renewed Adastra’s Controlled THCa diamonds, 1g Vaporizer Cartridge flavours, • Phyto Extr
Slide 5: Key Product Offerings
KEY PRODUCT OFFERINGS INFUSED FLOWER HYDROCARBON CRYO ETHANOL & PRE-ROLLS Distillate Vape Cartridges Live Resin, Shatter, THCa Pre-Rolls, Infused Pre-Rolls, Infused Diamonds, Full Spectrum Vape Milled Flower Cartridges, Sugar Wax, Crumble, CBD Isolate DRIED FLOWER FULL SPECTRUM SUPER/SUB CRITICAL CO
Slide 6: A Platform for Accelerated Growth in Canada
A PLATFORM FOR ACCELERATED GROWTH IN CANADA EXTRACT • Extraction methodologies and industry-leading equipment are designed to meet product development requirements, market demands and Health Canada quality standards SCIENCE • Cannabis processing, innovative product development and formulations, R&D,
Slide 7: Robust Extraction Capabilities
ROBUST EXTRACTION CAPABILITIES • Adastra Labs is a Health Canada licensed Standard Processor, cannabis product formulator and co-manufacturer for its in-house brands and many brand partners • 13,500 sq. ft facility and co-located analytical testing lab is located in Langley, BC, Canada • Adastra Lab
Slide 8: Adastra Analytics
ADASTRA ANALYTICS IN-HOUSE TESTING LAB • Licensed by Health Canada in 2019, Adastra Analytics is Adastra Labs' co-located analytical testing lab • Adastra conducts in-process cannabinoid potency testing, enhancing process efficiency and product quality assurance. It also offers QA/ QC and compliance
Slide 9: Owns 100% of Two Top-Performing Canadian Concentrates Brands
OWNS 100% OF TWO TOP-PERFORMING CANADIAN CONCENTRATES BRANDS AWARD-WINNING EXTRACTS • Phyto Extractions is a legacy purveyor of award-winning extracts. A household name in branded cannabis concentrates, like shatter • Founded in 2014 and acquired by Adastra in September 2021, Phyto Extractions brand
Slide 10: PerceiveMD Medical Cannabis Clinics
One Of British Columbia’s Leading Medical Cannabis And Forward-thinking Therapy Clinics PerceiveMD is a multidisciplinary team-based, patient-focused centre providing free, comprehensive assessments for medical cannabis. September 2021: Purchased 100% Of PerceiveMd (1) Combined with Adastra's medica
Slide 11: Growing Product Portfolio & Availability
GROWING PRODUCT PORTFOLIO & AVAILABILITY GROWTH DRIVERS EXPANDING RETAIL SALES DISTRIBUTION • Introduction of new products, into desired categories • Retail & market penetration • More than 2,000 Canadian retailers' stock Adastra products • New channels distribution regions • Expansion into maritime
Slide 12: Sustaining Momentum
SUSTAINING MOMENTUM Q4 2022 • Gross revenues of $6.8M for Q4 2022 compared to $2.0M for Q4 2021, representing a 243% increase 205% year-over-year growth • Gross profits of $2.6M, increase of 274% from Q4 2021 • Record Q4 2022 income before other items of $642K compared to loss before other items of $
Slide 13: YTD 2022 Financial Metrics
YTD 2022 FINANCIAL METRICS REVENUE Fiscal 2022 Fiscal 2021 % Change $13.3M Revenue $13,295,078 $5,628,616 136% Y/Y GROWTH Cost of Sales ($7,183,029) ($3,684,925) 95% 136% Gross Profit $6,112,049 $1,943,691 214% Gross Margin 46% 35% 33% GROSS PROFIT $6.1M Operating Expenses $6,912,045 $4,335,429 59% N
Slide 14: Capital Structure
CAPITAL STRUCTURE Shares Outstanding CSE: XTRX Total Shares TICKER (as of June 30, 2023) Common Shares 55,970,547 $0.105-$2.00 Options 2,870,000 52 WEEK RANGE Warrants 122,727 28% Total Shares Outstanding (Fully Diluted) 58,963,274 INSIDERS(1) Reserve for issuance 2,992,727 (1) Calculated as of May
Slide 15: Experienced Leadership Team
EXPERIENCED LEADERSHIP TEAM Michael Forbes Jean-Paul Lim BSC. PHARM MD, FRCPC CEO & DIRECTOR CHIEF STRATEGIC ADVISOR With a background firmly rooted in medicine, cannabis production and Jean Paul has a BSc in Microbiology, an entrepreneurship, Michael has founded five medical cannabis clinics, under M
Slide 16: Disclaimer
DISCLAIMER Investors and prospective investors should rely only on the information contained in the disclosure filings (the "Filings") of Adastra Holdings Ltd. (the "Company"). This presentation is qualified in its entirety by reference to, and must be read in conjunction with, the information contain
Slide 17: Get In Touch With Us
Get In Touch With Us MICHAEL FORBES CEO & DIRECTOR michael@adastraholdings.ca +1 (250) 882-3784
Adastra Holdings — Investor Presentation (September 2023) on 6ix